Kenjiro Sato

This inventor holds 13 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Takeda Pharmaceutical Company Limited, Cornell University, Tri-Institutional Therapeutics Discovery Institute. Active years: 1984-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenjiro Sato. Retrieved from https://idiyas.com/inventor/kenjiro-sato

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 2)

% Patents Active = 61.5

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

Aichi, JP (1984)
Nagoya, JP (2010)
Okayama, JP (2011)
Osaka, JP (2011)
Fujisawa, JP (2022)
Kanagawa, JP (2015 - 2023)

Company Filing History:

6 out of 1,229

Takeda Pharmaceutical Company Limited

Tri-Institutional Therapeutics Discovery Institute

patents

4. 2 out of 248

Daido Tokushuko Kabushiki Kaisha

6. 3 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1984-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12767667 - Macrocyclic heterocycle compounds and use thereof (2026-10-20),

2. 12473331 - Macrocyclic compounds as proteasome inhibitors (2025-11-18),

3. 11834515 - Macrocyclic compounds as proteasome inhibitors (2023-12-05),

4. 11732005 - Peptidomimetic proteasome inhibitors (2023-08-22),

5. 11495331 - Document creation assistance server and document creation assistance method (2022-11-08),

6. 11203613 - Peptidomimetic proteasome inhibitors (2021-12-21),

7. 10919891 - Heterocyclic compound (2021-02-16),

8. 9475822 - Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors (2016-10-25),

9. 9212149 - Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors (2015-12-15),

10. 8020229 - Pillow (2011-09-20),

11. 7915267 - Heterocyclic amide compound and use thereof (2011-03-29),

12. 7722801 - Vacuum carburizing apparatus (2010-05-25),

13. 4479535 - Recuperative radiant tube (1984-10-30),

Title: Kenjiro Sato: Innovator in Macrocyclic Compounds

Introduction

Kenjiro Sato is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of macrocyclic compounds. With a total of 13 patents, Sato's work has the potential to impact various medical treatments.

Latest Patents

Sato's latest patents focus on macrocyclic compounds as proteasome inhibitors. These compounds are represented by specific formulas where the substituents R, R, R, R, R, R, R', R″, X, Y, and Z are defined. The applications of these compounds include the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases, inflammatory disorders, and muscular dystrophy. Additionally, they can provide immunosuppression for transplanted organs or tissues.

Career Highlights

Throughout his career, Kenjiro Sato has worked with notable organizations, including Takeda Pharmaceutical Company Limited. His innovative research has led to advancements in the pharmaceutical industry, particularly in the development of new therapeutic agents.

Collaborations

Sato has collaborated with esteemed colleagues such as Hiroshi Nara and Wenhu Zhan. These partnerships have contributed to the success of his research and the advancement of his inventions.

Conclusion

Kenjiro Sato's contributions to the field of macrocyclic compounds and proteasome inhibitors highlight his role as a significant inventor in the pharmaceutical industry. His work continues to pave the way for new treatments and innovations in medicine.

Profile summary based on public USPTO records.